XML 42 R7.htm IDEA: XBRL DOCUMENT v2.4.0.8
Consolidated Statements of Cash Flows (unaudited) (USD $)
In Thousands, unless otherwise specified
 9 Months Ended 141 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Cash flows used in operating activities:      
Net loss $ (3,993) $ (3,480) $ (71,987)
Adjustments to reconcile net loss to net cash used in operating activities:      
Gain on patent rights assignment     (2,000)
Gain on bargain purchase     (25,282)
Depreciation and amortization 24 34 1,804
Non-cash interest expense     211
Share-based compensation 125 243 2,713
Issuance of warrants for lease termination     377
Accretion of liabilities     152
Impairment of property and equipment     125
Loss on impairment of in-process research and development     6,000
Write-off of deferred tax liability     (2,281)
Gain on marketable securities available for sale     (263)
(Gain) loss from disposal of property and equipment     83
Other, net     267
Change in operating assets and liabilities (net of amounts acquired):      
Other current assets (80) 219 2,740
Other assets 44 60 7,370
Accounts payable 382 (141) (1,743)
Accrued expenses and other liabilities 98 (318) (19,123)
Deferred rent (16) (25)  
Net cash used in operating activities (3,416) (3,408) (100,837)
Cash flows (used in) provided by investing activities:      
Cash received from Merger     30,392
Payment of deferred transaction costs     (1,186)
Purchase of property and equipment (28) (1) (1,907)
Proceeds from sale of marketable securities     15,369
Proceeds from sale of property and equipment     358
Proceeds from patent rights assignment     2,000
Net cash (used in) provided by investing activities (28) (1) 45,026
Cash flows provided by (used in) financing activities:      
Proceeds from issuance of convertible notes payable and related warrants for common stock     10,841
Proceeds from issuance of bank note payable     4,000
Proceeds from stock subject to repurchase     38
Proceeds from the issuance of preferred stock 20,000   52,316
Payment of offering costs 20    
Proceeds from the issuance of common stock 1,741 953 15,850
Repayment of principal on bank note payable     (4,000)
Repayment of principal on convertible notes payables     (105)
Repayment of principal on vendor finance agreement (174) (134) (454)
Net cash provided by (used in) financing activities 19,156 547 74,443
Net increase (decrease) in cash and cash equivalents 15,712 (2,862) 18,632
Cash and cash equivalents, beginning of period 2,920 5,943  
Cash and cash equivalents, end of period 18,632 3,081 18,632
Supplemental cash flow information:      
Interest paid 3 3 118
Supplemental disclosure of noncash investing and financing transactions:      
Accrued interest on notes payable converted to equity     163
Warrant issued in connection with credit facility     111
Accrued deferred transaction costs     482
Vendor finance agreement         
Preferred Stock
      
Cash flows provided by (used in) financing activities:      
Payment of offering costs (2,083)   (2,329)
Common Stock
      
Cash flows provided by (used in) financing activities:      
Payment of offering costs $ (328) $ (272) $ (1,714)